Personalized medicine in rheumatoid arthritis: Hopes and challenges

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 174-177

  Louis Bridges Jr , S ^a,b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GEFITINIB; HLA DR ANTIGEN; INFLIXIMAB; MERCAPTOPURINE; PRIMAQUINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; THIOPURINE METHYLTRANSFERASE; ANTIRHEUMATIC AGENT; METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

COST EFFECTIVENESS ANALYSIS; DRUG METABOLISM; DRUG WITHDRAWAL; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; GENOMICS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LUNG CANCER; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PHARMACOGENETICS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETIC MARKER; GENETICS; GENOTYPE; IMMUNOLOGY; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; GENETIC MARKERS; GENOTYPE; HUMANS; METHYLTRANSFERASES; PHARMACOGENETICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449096755     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (26)

1. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26.
2. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2006 Oct;20(5):865-78.
3. Silverstein AM. A History of Immunology. San Diego, CA: Harcort, Brace, Jovanovich. Academic Press, Inc.,1989.
4. Vogel F. Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheilkd. 1959;12:52.
5. Beutler E. Drug-induced hemolytic anemia. Pharmacol Rev. 1969 Mar;21(1):73-103.
6. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998 Sep;281(5384):1820-1.
7. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119-37.
8. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003 Feb;348(6):529-37.
9. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003 Feb;348(6):538-49.
10. Bridges SL, Jr. Spotting aggressive RA early: The physical examination, testing, and imaging. J Musculoskeletal Med. 2006;23(11 Suppl):S10-4.
11. Kirwan JR. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol. 1999 Mar;26(3):720-5.
12. Bridges SL Jr. The genetics of rheumatoid arthritis: Influences on susceptibility, severity, and treatment response. Curr Rheumatol Rep. 1999 Dec;1(2):164-71.
13. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun. 2004 Aug;5(5):315-29.
14. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun;304(5676):1497-500.
15. Wadman M. Drug targeting: Is race enough? Nature. 2005 June;435(7045):1008-9.
16. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006 Feb;6(2):117-29.
17. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998 Nov;129(9):716-8.
18. O'Dell JR, Nepom BS, Haire C, et al. HLA-DRB1 typing in rheumatoid arthritis: Predicting response to specific treatments. Ann Rheum Dis. 1998;57(4):209-13.
19. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004;50(9):2750-6.
20. Bridges SL Jr. Genetic markers of treatment response in rheumatoid arthritis. Arthritis Rheum. 2004;50:1019-22.
21. Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64(8):1180-5.
22. Weisman MH, Furst DE, Park GS, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum. 2006;54(2):607-12.
23. Hughes LB, Beasley TM, Patel H, et al. Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2006;65(9):1213-8.
24. Kremer JM. Methotrexate pharmacogenomics. Ann Rheum Dis. 2006;65(9):1121-3.
25. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990):464-8.
26. Cronstein BN. Pharmacogenetics in the rheumatic diseases, from pret-a-porter to haute couture. Nat Clin Pract Rheumatol. 2006;2(1):2-3.